US FDA clears investigational new drug application for CRISPR/Cas13 RNA-editing therapy

News
Article

HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration

An eye with digitally-rendered transparent DNA strands in front of it. Image credit: ©kittyfly – stock.adobe.com

Strong preclinical data for HG202 and promising results from the first-in-human ‘SIGHT-I’ trial in China underscored its potential to address AMD. Image credit: ©kittyfly – stock.adobe.com

The US Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for HG202, by HuidaGene Therapeutics, a company with headquarters in Shanghai, China, and Clinton, New Jersey. According to a press release, the drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD).

Alvin Luk, PhD, MBA, CCRA, the co-founder and CEO of HuidaGene, commented on the milestone in the company's press release. He said, “This open IND for HG202 by the US FDA-the first regulator to clear CRISPR/Cas13 for clinical development–marks a significant milestone for HuidaGene and the CRISPR RNA-editing field. The strong preclinical data for HG202, combined with promising results from the first-in-human ‘SIGHT-I’ trial in China, underscored its potential to address AMD using a non-receptor binding pathway through the Cas13 RNA editor to knockdown VEGF-A mRNA.”

Xin Zhang, MD, MSc, COO and CMO of HuidaGene, highlighted the importance and urgency of developing new nAMD treatments to benefit patients worldwide, saying “Up to 46% of AMD patients respond poorly or develop resistance to anti-VEGF therapies. AMD patients deserve safe, effective treatment options. The BRIGHT trial will evaluate HG202’s safety and efficacy to address this gap. We look forward to enrolling patients soon.”

Similarly, Hui Yang, PhD, the co-Founder and chief scientific advisor of the company shared his thoughts and explained the technical side of this candidate, saying, “Our AI/ML-driven HG-PRECISE platform led us to discover the Cas13X/Y system (Nature Methods 2021). Building on this basis, my team engineered high-fidelity Cas13Y with efficient editing and low off-target effects (Nature Biotechnology 2022), laying out the technical foundation for future clinical applications.”

BRIGHT Trial of HG202 (NCT06623279)

The BRIGHT trial is a phase 1, open-label, dose-escalation study for CRISPR/Cas13-RNA targeting therapy for the treatment of neovascular AMD. Primary endpoints include the safety and tolerability of HG202, with secondary endpoints assessing improvements in visual acuity, retinal thickness, and the need for anti-VEGF injections.

Reference:
1. HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration. HuidaGene Therapeutics. November 4, 2024. Accessed November 12, 2024. https://www.biospace.com/press-releases/huidagene-therapeutics-receives-the-first-ever-fda-clearance-of-crispr-cas13-rna-editing-hg202-for-macular-degeneration

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.